Cargando…

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity

The antiangiogenic agent bevacizumab showed synergistic effects when combined with chemotherapy in advanced breast cancer. We presently investigated the activity of bevacizumab in combination with chemotherapy, including capecitabine and vinorelbine, and endocrine therapy, including letrozole (+trip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torrisi, R, Bagnardi, V, Cardillo, A, Bertolini, F, Scarano, E, Orlando, L, Mancuso, P, Luini, A, Calleri, A, Viale, G, Goldhirsch, A, Colleoni, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584958/ https://www.ncbi.nlm.nih.gov/pubmed/18941458 http://dx.doi.org/10.1038/sj.bjc.6604741

Ejemplares similares

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
por: Montagna, E, et al.
Publicado: (2008)

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2022)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study
por: Paleari, Laura, et al.
Publicado: (2020)

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer
por: Dobrescu, Andrei, et al.
Publicado: (2011)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies
por: Zhou, Chen, et al.
Publicado: (2022)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Association of +331G/A PgR Polymorphism with Susceptibility to Female Reproductive Cancer: Evidence from a Meta-Analysis
por: Chaudhary, Sanjib, et al.
Publicado: (2013)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
por: Sorbye, Sveinung W, et al.
Publicado: (2013)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Prevalence of ERα-397 PvuII C/T, ERα-351 XbaI A/G and PGR PROGINS polymorphisms in Brazilian breast cancer-unaffected women
por: Giacomazzi, J., et al.
Publicado: (2012)

Compendio informativo PGR : órgano de difusión de la Procuraduría General de la República.
Publicado: (1995)

Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
por: Cuppini, Lucia, et al.
Publicado: (2013)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Nuclear Progestin Receptor (Pgr) Knockouts in Zebrafish Demonstrate Role for Pgr in Ovulation but Not in Rapid Non-Genomic Steroid Mediated Meiosis Resumption
por: Zhu, Yong, et al.
Publicado: (2015)

Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016)

NTRC Effects on Non-Photochemical Quenching Depends on PGR5
por: Naranjo, Belen, et al.
Publicado: (2021)

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence
por: Conforti, Fabio, et al.
Publicado: (2019)

Identification of a Novel Mutation Exacerbated the PSI Photoinhibition in pgr5/pgrl1 Mutants; Caution for Overestimation of the Phenotypes in Arabidopsis pgr5-1 Mutant
por: Wada, Shinya, et al.
Publicado: (2021)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma
por: Mancuso, Patrizia, et al.
Publicado: (2010)

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
por: Orecchioni, Stefania, et al.
Publicado: (2018)

Knockdown of Progesterone Receptor (PGR) in Macaque Granulosa Cells Disrupts Ovulation and Progesterone Production
por: Bishop, Cecily V., et al.
Publicado: (2016)

Progesterone Receptor (PGR) gene polymorphism is associated with susceptibility to preterm birth
por: Langmia, Immaculate Mbongo, et al.
Publicado: (2015)

PGRL2 triggers degradation of PGR5 in the absence of PGRL1
por: Rühle, Thilo, et al.
Publicado: (2021)

Chemical Structures and Pharmacological Properties of Typical Bioflavonoids in Polygonati Rhizoma (PGR)
por: Luo, Min, et al.
Publicado: (2022)

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
por: Munzone, E., et al.
Publicado: (2021)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
por: Schöffski, Patrick, et al.
Publicado: (2018)

miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer
por: Yu, Tao, et al.
Publicado: (2017)

Protective Role of the PG1036-PG1037-PG1038 Operon in Oxidative Stress in Porphyromonas gingivalis W83
por: Henry, Leroy G., et al.
Publicado: (2013)

In Vivo Genome-Wide PGR Binding in Pregnant Human Myometrium Identifies Potential Regulators of Labor
por: Dotts, Ariel J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_657pft7ubqarnt9r1hkpr19qp4